Skip to content
Saturday 8 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Astrazeneca

  • Astrazeneca pauses £200m Cambridge investment

    September 13, 2025

    British drug giant Astrazeneca has paused a planned £200 million expansion of its research site in Cambridge in a fresh blow to the UK pharmaceutical industry. It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year in a blow to the Government as it [...]

  • Merck warns UK is ‘not internationally competitive’ as it scraps £1bn London research centre

    September 10, 2025

    Merck has pulled out of a planned £1bn London drug research centre in the latest blow to the government’s growth agenda. The US pharma giant is to lay off 127 staff alongside abandoning the construction project, which had been set to open in King’s Cross in 2027. The firm warned the UK would lag behind [...]

  • Pharma stocks suffer as Trump demands prescription slash

    August 1, 2025

    Pharmaceutical stocks across the global markets have taken a hit after Trump demanded drug companies lower prices for American consumers. Trump’s threat against pharmaceuticals has given healthcare sector investors “a dose of the blues” after his letter to various company bosses. It outlined that they should either cut US prescription prices or face a tariff [...]

  • Could Astrazeneca completely switch its allegiance to the US?

    July 30, 2025

    The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient at the lacklustre performance of the London Stock Exchange. Chief among them is pharmaceutical giant Astrazeneca, which cancelled plans for a Liverpool vaccine plant due to lack of economic support earlier this year and has expressed frustration [...]

  • Astrazeneca plots huge $50bn US investment after ditching UK expansion plans

    July 22, 2025

    Astrazeneca has unveiled plans to invest as much as $50bn in manufacturing and R&D in the US after ditching its UK expansion plans in a blow to the government’s industrial strategy. The Cambridge-based pharma giant said it will spend the huge sum over the next five years, including on a new manufacturing facility in Virginia, [...]

  • Trump tariffs: FTSE 100 holds steady as pharma and metals brace for levies

    July 9, 2025

    The FTSE 100 opened 22 points up this morning, despite threats of pharma and metals tariffs with stark implications for major stocks on the blue chip index.  President Trump has said that an announcement is coming “very soon” on pharmaceutical tariffs – with a possible 200 per cent rate landing in “about a year”.  Major [...]

  • These charts show the scale of the London Stock Exchange’s decline

    July 9, 2025

    In May, one of the London Stock Exchange’s smallest constituents decided to leave. Brighton Pier, which had been listed on the exchange’s AIM market with a £5m market cap, delisted and jumped ship to private securities venue JP Jenkins. “It’s something that had been building up for quite a while for the past several years,” [...]

  • Astrazeneca chief ‘wants to shift London listing to US’

    July 1, 2025

    The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock market listing to the United States. Sir Pascal Soriot, who has been at the helm of the pharma juggernaut since 2012, is said to have spoken privately about his desire to abandon the UK listing in favour [...]

  • GSK and Astrazeneca shares slump as Trump vows drug price cut

    May 12, 2025

    GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.

  • FTSE 100’s record run ends as pharma stocks slide on new Trump appointment 

    May 7, 2025

    The FTSE 100’s record run came to an end on Wednesday as pharma stocks slumped on the back of a controversial US regulatory appointment.  The blue-chip index spent the entire session in the red and closed off 0.4 per cent. Drugmakers GSK and Astrazeneca were among the top fallers, at nearly five per cent and [...]

Posts pagination

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Page 27
  • Next

Trending Articles

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Starling plans to ‘come out swinging’ in diversification bid

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook